Glutamatergic Modulators for Major Depression from Theory to Clinical Use
Open accessThe DOI matches its Crossref record; 133 of the 133 references it cites were found in a registry or an index.
Abstract
Major depressive disorder (MDD) is a chronic, burdensome, highly prevalent disease that is characterized by depressed mood and anhedonia. MDD is especially burdensome as approved monoamine antidepressant treatments have weeks-long delays before clinical benefit and low remission rates. In the past 2 decades, a promising target emerged to improve patient outcomes in depression treatment: glutamatergic signaling. This narrative review provides a high-level overview of glutamate signaling in synaptogenesis and neural plasticity and the implications of glutamate dysregulation in depression. Based on this preclinical evidence implicating glutamate in depression and the rapid improvement of depression with ketamine treatment in a proof-of-concept trial, a range of N-methyl-d-aspartate (NMDA)-targeted therapies have been investigated. While an array of treatments has been investigated in registered phase 2 or 3 clinical trials, the development of most of these agents has been discontinued. Multiple glutamate-targeted antidepressants are actively in development, and two are approved. Nasal administration of esketamine (Spravato®) was approved by the US Food and Drug Administration (FDA) in 2019 to treat adults with treatment-resistant depression and in 2020 for adults with MDD with acute suicidal ideation or behavior. Oral combination dextromethorphan–bupropion (AXS-05, Auvelity® extended-release tablet) was FDA approved in 2022 for the treatment of MDD in adults. These approvals bolster the importance of glutamate in depression and represent an exciting breakthrough in contemporary psychiatry, providing new avenues of treatment for patients as first-line therapy or with either poor response or unacceptable side effects to monoaminergic antidepressants. Major depressive disorder (MDD) is a common disease defined by sadness and a loss of interest or pleasure in activities. Depression treatments include therapy and antidepressant medication. Most available antidepressants affect the same types of chemicals that communicate in the brain (neurotransmitters) called monoamines. Unfortunately, these medicines can take weeks to work for some people and many still have depression symptoms with treatment. To provide more treatment options, new medicines have been studied that impact a different neurotransmitter in the brain, that is, glutamate. Glutamate, the most abundant neurotransmitter, is important for the growth of new brain cell connections, and there are changes in glutamate in people with depression versus people without depression. In 2000, the first small study in people showed that ketamine, a medicine targeting glutamate, quickly improved depression symptoms. Safety risks, including dissociation and sedation, require supervised administration and management guidance. Since 2000, about 20 glutamate-targeted medicines have been tested in human clinical trials. Two of these are approved as antidepressants. The medicine esketamine, which is inhaled up the nose at a clinic under medical supervision, is approved for the adjunctive treatment of people with MDD whose symptoms do not improve with other treatments or who have suicidal thoughts or actions (brand name Spravato®). The combination medicine dextromethorphan–bupropion is a swallowed tablet taken twice daily that is an approved monotherapy to treat adults with MDD (brand name Auvelity®). The approval of these drugs helps show the importance of glutamate in depression and provides more options for people with depression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Glutamate signaling in neuroplasticity and synaptogenesis. Akt protein kinase B, AMPAR α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor, BDNF brain-derived neurotrophic factor, EAAT excitatory amino acid transporter, EF2 eukaryotic elongation factor 2, ERK extracellular signal-regulated kinases, Gln glutamine, Glu glutamate, mGluR metabotropic glutamate receptor, mTOR mammalian target of rapamycin, NMDAR N-methyl-d-aspartate receptor, P phosphorylated, TrkB tropomyosin receptor kinase B, vGLUT vesicular glutamate transporter. Modified from Lener et al. 2017 [162] and Henter et al. 2021 [14]. Figure illustration elements modified from Servier Medical Art (2022) by Servier (https://smart.servier.com, used under a Creative Commons Attribution 4.0 License)](https://figures.cochat.ai/paper-figures/68ef3373bc64473084336bf4d3222e9b/glutamatergic-modulators-for-major-depression-from-theory-to-clinical-use-figure-1.jpg)
![Fig. 2 Timeline of registered trials of glutamate-targeted drugs for treatment of depressiona. aFigure includes phase 2, 3, and 4 trials registered on ClinicalTrials.gov for the treatment of MDD or TRD as detailed in Online Resource 1, Supplementary Table 1. bThe first placebo-controlled, double-blind trial of ketamine in seven people with depression, conducted in 2000, was not registered on ClinicalTrials.gov [64]. cIntranasal esketamine is approved by the FDA, TPD, EMA, and TGA as an adjunctive treatment for TRD and/or for MDD with suicidal ideation/behavior or psychiatric emergency. dAXS-05 is approved to treat MDD in adults by the FDA. EMA European Medicines Agency, FDA US Food and Drug Administration, MDD major depressive disorder, NMDA N-methyl d-aspartate, TGA Australia’s Therapeutic Goods Administration, TPD Canada’s Therapeutic Products Directorate, TRD treatment-resistant depression](https://figures.cochat.ai/paper-figures/edf97bb37e3e4d8cbb81601f2d178b1a/glutamatergic-modulators-for-major-depression-from-theory-to-clinical-use-figure-2.jpg)
![Fig. 3 Response and remission rates with adjunctive intranasal esketamine in TRANSFORM-2 triala,b. aTRANSFORM-2 (NCT02418585) investigated adjunctive flexibly dosed intranasal esketamine versus adjunctive placebo with a newly initiated oral SNRI or SSRI antidepressant, in patients with TRD in a 28-day double-blind treatment phase. bPercentages shown are the proportion of patients remaining at visit [127]. ADT antidepressant, IN intranasal, MADRS Montgomery-Åsberg Depression Rating Scale, SNRI serotonin-norepinephrine reuptake inhibitor, SSRI selective serotonin reuptake inhibitor, TRD treatment-resistant depression, NR not reported](https://figures.cochat.ai/paper-figures/e2bc8d1fcaa9445b8a3691f901fd5e97/glutamatergic-modulators-for-major-depression-from-theory-to-clinical-use-figure-3.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Esketamine provides a more NMDAR-centered entry into the induction pathway described above, producing rapid clinical effects but also transient dissociation and sympathomimetic effects [45,46,47,49,52,55,56].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [52]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Common adverse effects include dissociation, dizziness, and blood pressure (BP) elevation [52,53,55].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [52]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
James, S. L., Abate, D., Abate, K. H., Abay, S. M., Abbafati, C., Abbasi, N., Abbastabar, H., Abd-Allah, F., Abdela, J., Abdelalim, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32279-7 · Cited by 13,867
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
The American Psychological Association
Langfeld, H. S. (1919) · Science · doi:10.1126/science.49.1254.51 · Cited by 7,475
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879 · cited 2×
“Depression is especially burdensome due to the low rates of remission associated with current monoamine antidepressant treatments [15, 16].”
BackgroundAntidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881 · cited 1×
“…of eukaryotic elongation factor 2 (eEF2), allowing for protein translation [45]. mTOR activation thus increases the expression of synaptic proteins vital for the formation, maturation, and function of synaptic spines and can lead to increases in the density of dendritic spines [44–47].”
BackgroundRisks of all-cause and suicide mortality in mental disorders: a meta-review
Chesney, E., Goodwin, G. M., & Fazel, S. (2014) · World Psychiatry · doi:10.1002/wps.20128 · Cited by 2,115 · cited 2×
“These efficacy limitations with monoamine antidepressants may also demoralize patients and contribute to the increased risk of suicide in people with depression [8].”
BackgroundGlutamate: A Neurotransmitter in Mammalian Brain
Fonnum, F. (1984) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1984.tb09689.x · Cited by 1,992
Epidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States
Hasin, D. S., Sarvet, A. L., Meyers, J. L., Saha, T. D., Ruan, W. J., Stohl, M., & Grant, B. F. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.4602 · Cited by 1,737 · cited 1×
“Major depressive disorder (MDD) is a highly prevalent disease, and depressive disorders have been a leading cause of chronic disease burden worldwide for the past 3 decades [1, 2].”
BackgroundMaeng, S., Zarate, C. A., Du, J., Schloesser, R. J., McCammon, J., Chen, G., & Manji, H. K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.028 · Cited by 1,103 · cited 1×
“Rodent models support the importance of AMPAR activation and increased BDNF as essential for depression improvement with ketamine, as antidepressant effects are not observed if BDNF is neutralized or AMPAR inhibited [58, 59].”
BackgroundLi, N., Liu, R.-J., Dwyer, J. M., Banasr, M., Lee, B., Son, H., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.12.015 · Cited by 1,082
Towards a glutamate hypothesis of depression
Sanacora, G., Treccani, G., & Popoli, M. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.07.036 · Cited by 1,036
Duman, R. S., Sanacora, G., & Krystal, J. H. (2019) · Neuron · doi:10.1016/j.neuron.2019.03.013 · Cited by 1,026 · cited 3×
“Stress and depression can also dysregulate GABA function, which causes imbalances between excitatory and inhibitory activity [51].”
BackgroundRisk for recurrence in depression
Burcusa, S. L., & Iacono, W. G. (2007) · Clinical Psychology Review · doi:10.1016/j.cpr.2007.02.005 · Cited by 1,023
Popova, V., Daly, E. J., Trivedi, M., Cooper, K., Lane, R., Lim, P., Mazzucco, C., Hough, D., Thase, M. E., Shelton, R. C., et al. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19020172 · Cited by 904 · cited 1×
“…esketamine versus placebo to treat TRD (Table 2), both adjunctive to a newly initiated oral SNRI or SSRI antidepressant, there was significantly greater improvement in the esketamine group at day 28 [ P 0.05 for adjunctive esketamine ( n = 114) versus adjunctive placebo ( n = 109)] [127].”
BackgroundInfluentialMcIntyre, R. S., Alsuwaidan, M., Baune, B. T., Berk, M., Demyttenaere, K., Goldberg, J. F., Gorwood, P., Ho, R., Kasper, S., Kennedy, S. H., et al. (2023) · World Psychiatry · doi:10.1002/wps.21120 · Cited by 836 · cited 3×
“…inhibitors (MAOIs), tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), serotonin–norepinephrine reuptake inhibitors (SNRIs), and atypical antidepressants (e.g., bupropion, mirtazapine), inadequate or partial response is still common in MDD treatment [13, 14, 17].”
BackgroundSelf-citationDaly, E. J., Trivedi, M. H., Janik, A., Li, H., Zhang, Y., Li, X., Lane, R., Lim, P., Duca, A. R., Hough, D., et al. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.1189 · Cited by 795
Functional antagonists at the NMDA receptor complex exhibit antidepressant actions
Trullas, R., & Skolnick, P. (1990) · European Journal of Pharmacology · doi:10.1016/0014-2999(90)90204-j · Cited by 785 · cited 1×
“A preclinical study in 1990 first indicated that NMDA receptor antagonists mimicked the clinical effects of antidepressants in murine models, leading to the glutamate hypothesis of depression [53].”
BackgroundMcIntyre, R. S., Rosenblat, J. D., Nemeroff, C. B., Sanacora, G., Murrough, J. W., Berk, M., Brietzke, E., Dodd, S., Gorwood, P., Ho, R., et al. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20081251 · Cited by 731 · cited 9×
“The bioavailability of ketamine is highest with intravenous administration, and it is the most widely researched formulation for the acute treatment of depression [66].”
BackgroundMethodInfluentialSelf-citationDaly, E. J., Singh, J. B., Fedgchin, M., Cooper, K., Lim, P., Shelton, R. C., Thase, M. E., Winokur, A., Van Nueten, L., Manji, H., et al. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.3739 · Cited by 718
Canuso, C. M., Singh, J. B., Fedgchin, M., Alphs, L., Lane, R., Lim, P., Pinter, C., Hough, D., Sanacora, G., Manji, H., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.17060720 · Cited by 676
Carvalho, A. F., Sharma, M. S., Brunoni, A. R., Vieta, E., & Fava, G. A. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000447034 · Cited by 650
How do antidepressants work? New perspectives for refining future treatment approaches
Harmer, C. J., Duman, R. S., & Cowen, P. J. (2017) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30015-9 · Cited by 616
Fedgchin, M., Trivedi, M., Daly, E. J., Melkote, R., Lane, R., Lim, P., Vitagliano, D., Blier, P., Fava, M., Liebowitz, M., et al. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz039 · Cited by 606
Brain-Derived Neurotrophic Factor Signaling in Depression and Antidepressant Action
Castrén, E., & Monteggia, L. M. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2021.05.008 · Cited by 540
Zhdanava, M., Pilon, D., Ghelerter, I., Chow, W., Joshi, K., Lefebvre, P., & Sheehan, J. J. (2021) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.20m13699 · Cited by 523 · cited 2×
“The unmet need with monoamine therapies is further highlighted as approximately 30% of patients undergoing pharmacotherapy for MDD have treatment-resistant depression (TRD) [17, 30].”
BackgroundAttenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism
Williams, N. R., Heifets, B. D., Blasey, C., Sudheimer, K., Pannu, J., Pankow, H., Hawkins, J., Birnbaum, J., Lyons, D. M., Rodriguez, C. I., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18020138 · Cited by 519
Preskorn, S. H., Baker, B., Kolluri, S., Menniti, F. S., Krams, M., & Landen, J. W. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31818a6cea · Cited by 518
Stahl, S. M., Pradko, J., Haight, B. R., Modell, J. G., Rockett, C. B., & Learned-Coughlin, S. (2004) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v06n0403 · Cited by 495 · cited 1×
“In addition to serving as metabolic inhibitor of cytochrome P450 2D6 [21], bupropion enhances monoaminergic function as a norepinephrine–dopamine reuptake inhibitor and is approved to treat MDD (target dose 300 mg/day, maximum dose 450 mg/day) [136, 137].”
BackgroundLener, M. S., Niciu, M. J., Ballard, E. D., Park, M., Park, L. T., Nugent, A. C., & Zarate, C. A. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.05.005 · Cited by 468
Treatment-resistant depression: Definitions, review of the evidence, and algorithmic approach
McIntyre, R. S., Filteau, M.-J., Martin, L., Patry, S., Carvalho, A., Cha, D. S., Barakat, M., & Miguelez, M. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.10.043 · Cited by 421 · cited 2×
“A principal goal in MDD treatment is to reach full remission and return to normal functioning, in which functional impairment at work and/or in the home has also resolved [9].”
BackgroundSelf-citationFeyissa, A. M., Chandran, A., Stockmeier, C. A., & Karolewicz, B. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.10.005 · Cited by 421 · cited 1×
“Positron emission tomography (PET) imaging studies and postmortem tissue analyses have revealed abnormalities in NMDA receptor and mGluR subunit/protein expression in the prefrontal cortex in patients with MDD [60, 61].”
BackgroundIonescu, D. F., Fu, D.-J., Qiu, X., Lane, R., Lim, P., Kasper, S., Hough, D., Drevets, W. C., Manji, H., & Canuso, C. M. (2021) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa068 · Cited by 418
Fu, D.-J., Ionescu, D. F., Li, X., Lane, R., Lim, P., Sanacora, G., Hough, D., Manji, H., Drevets, W. C., & Canuso, C. M. (2020) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.19m13191 · Cited by 376
Franken, I. H. A., Rassin, E., & Muris, P. (2007) · Journal of Affective Disorders · doi:10.1016/j.jad.2006.08.020 · Cited by 373
BDNF release is required for the behavioral actions of ketamine
Lepack, A. E., Fuchikami, M., Dwyer, J. M., Banasr, M., & Duman, R. S. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu033 · Cited by 368
Moriguchi, S., Takamiya, A., Noda, Y., Horita, N., Wada, M., Tsugawa, S., Plitman, E., Sano, Y., Tarumi, R., ElSalhy, M., et al. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0252-9 · Cited by 357
Brain-derived neurotrophic factor in mood disorders and antidepressant treatments
Castrén, E., & Kojima, M. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.07.010 · Cited by 337
Hashimoto, K. (2019) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12902 · Cited by 335 · cited 2×
“Note that, while ketamine is used off label to treat depression, it is only approved as an anesthetic (by FDA, TPD, TGA) and, as such, is not discussed here [68, 121, 122].”
BackgroundOverview of glutamatergic neurotransmission in the nervous system
Niciu, M. J., Kelmendi, B., & Sanacora, G. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.08.008 · Cited by 329
Wajs, E., Aluisio, L., Holder, R., Daly, E. J., Lane, R., Lim, P., George, J. E., Morrison, R. L., Sanacora, G., Young, A. H., et al. (2020) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.19m12891 · Cited by 308
Parati, G., Kjeldsen, S., Coca, A., Cushman, W. C., & Wang, J. (2021) · Hypertension · doi:10.1161/hypertensionaha.120.15781 · Cited by 281
Qaseem, A., Barry, M. J., Kansagara, D., & for the Clinical Guidelines Committee of the American College of Physicians (2016) · Annals of Internal Medicine · doi:10.7326/m15-2570 · Cited by 279 · cited 1×
“To this aim, treatment guidelines recommend shared decision-making with patients to select psychotherapy and/or pharmacotherapy, with a tailored approach for severe, recurrent, or persistent MDD [10–12].”
BackgroundDeschwanden, A., Karolewicz, B., Feyissa, A. M., Treyer, V., Ametamey, S. M., Johayem, A., Burger, C., Auberson, Y. P., Sovago, J., Stockmeier, C. A., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.09111607 · Cited by 278
Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression
Anand, A., Mathew, S. J., Sanacora, G., Murrough, J. W., Goes, F. S., Altinay, M., Aloysi, A. S., Asghar-Ali, A. A., Barnett, B. S., Chang, L. C., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2302399 · Cited by 276
Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability
Bonaventura, J., Lam, S., Carlton, M., Boehm, M. A., Gomez, J. L., Solís, O., Sánchez-Soto, M., Morris, P. J., Fredriksson, I., Thomas, C. J., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01093-2 · Cited by 271 · cited 1×
“In addition to acting as an NMDA receptor antagonist, esketamine is a sigma-1 agonist, with a weaker affinity for sigma-1 than the ( R )-ketamine enantiomer [129].”
BackgroundAcute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications
Cosci, F., & Chouinard, G. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000506868 · Cited by 265 · cited 1×
“However, as was the case with SSRIs and SNRIs, post-approval real-world data will be essential to confirm the safety profiles of the drugs and document potential adverse events or withdrawal syndrome that may arise with long-term use [148, 149].”
BackgroundZarate, C. A., Mathews, D., Ibrahim, L., Chaves, J. F., Marquardt, C., Ukoh, I., Jolkovsky, L., Brutsche, N. E., Smith, M. A., & Luckenbaugh, D. A. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.10.019 · Cited by 255 · cited 1×
“…compared with placebo in people with treatment-resistant MDD [NCT00986479, P 0.001 150 mg lanicemine versus placebo ( N = 22 crossover design)] [95] or moderate to severe MDD with a history of poor response [NCT00781742, P 0.01 for 100 mg lanicemine ( n = 51) versus placebo ( n = 50), P …”
BackgroundInfluentialMoitra, M., Santomauro, D., Degenhardt, L., Collins, P. Y., Whiteford, H., Vos, T., & Ferrari, A. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.02.053 · Cited by 252
Jaffe, D. H., Rive, B., & Denee, T. R. (2019) · BMC Psychiatry · doi:10.1186/s12888-019-2222-4 · Cited by 237
Sanacora, G., Smith, M. A., Pathak, S., Su, H.-L., Boeijinga, P. H., McCarthy, D. J., & Quirk, M. C. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.130 · Cited by 236
Adherence to HIV treatment regimens: systematic literature review and meta-analysis
Altice, F., Evuarherhe, O., Shina, S., Carter, G., & Beaubrun, A. C. (2019) · Patient Preference and Adherence · doi:10.2147/ppa.s192735 · Cited by 236
Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression
Reif, A., Bitter, I., Buyze, J., Cebulla, K., Frey, R., Fu, D.-J., Ito, T., Kambarov, Y., Llorca, P.-M., Oliveira-Maia, A. J., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2304145 · Cited by 222 · cited 1×
“…esketamine nasal spray adjunctive to a continuing SSRI or SNRI was superior to adjunctive extended-release quetiapine for the acute and continuation treatment of adults with TRD [remission at week 8; esketamine 27.1% (91/336) versus quetiapine 17.6% (60/340), adjusted P < 0.01] (Table 2) [128].”
InfluentialSim, K., Lau, W. K., Sim, J., Sum, M. Y., & Baldessarini, R. J. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv076 · Cited by 218 · cited 1×
“In patients who do achieve relief of depression symptoms, between 25 and 60% experience recurrence of depression [22, 23].”
BackgroundKetamine and depression: a narrative review
Corriger, A., & Pickering, G. (2019) · Drug Design, Development and Therapy · doi:10.2147/dddt.s221437 · Cited by 211
Gadad, B. S., Jha, M. K., Czysz, A., Furman, J. L., Mayes, T. L., Emslie, M. P., & Trivedi, M. H. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.07.001 · Cited by 205
PRESKORN, S., MACALUSO, M., MEHRA, D. V., ZAMMIT, G., MOSKAL, J. R., & BURCH, R. M. (2015) · Journal of Psychiatric Practice · doi:10.1097/01.pra.0000462606.17725.93 · Cited by 193
Pharmacology of dextromethorphan: Relevance to dextromethorphan/quinidine (Nuedexta®) clinical use
Taylor, C. P., Traynelis, S. F., Siffert, J., Pope, L. E., & Matsumoto, R. R. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.04.010 · Cited by 186
Alnefeesi, Y., Chen-Li, D., Krane, E., Jawad, M. Y., Rodrigues, N. B., Ceban, F., Di Vincenzo, J. D., Meshkat, S., Ho, R. C. M., Gill, H., et al. (2022) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2022.04.037 · Cited by 186
Self-citationAndrade, C. (2017) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.17f11738 · Cited by 178
The Involvement of Hypothalamus–Pituitary–Adrenal (HPA) Axis in Suicide Risk
Berardelli, I., Serafini, G., Cortese, N., Fiaschè, F., O’Connor, R. C., & Pompili, M. (2020) · Brain Sciences · doi:10.3390/brainsci10090653 · Cited by 177
The Dichotomy of NMDA Receptor Signaling
Papadia, S., & Hardingham, G. E. (2007) · The Neuroscientist · doi:10.1177/10738584070130060401 · Cited by 176
Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism
Williams, N. R., Heifets, B. D., Bentzley, B. S., Blasey, C., Sudheimer, K. D., Hawkins, J., Lyons, D. M., & Schatzberg, A. F. (2019) · Molecular Psychiatry · doi:10.1038/s41380-019-0503-4 · Cited by 174
Wilkinson, S. T., & Sanacora, G. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2018.11.007 · Cited by 173 · cited 1×
“Glial cells can express mGluRs, in addition to metabolizing glutamate to glutamine and releasing the NMDA receptor co-agonist d -serine [50]. mGluRs are often located outside of the synapses on neurons and glia, but they can still modulate synaptic activity and plasticity [38].”
BackgroundIgnácio, Z. M., Réus, G. Z., Arent, C. O., Abelaira, H. M., Pitcher, M. R., & Quevedo, J. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12845 · Cited by 172
C-Reactive protein as a biomarker for major depressive disorder?
Orsolini, L., Pompili, S., Tempia Valenta, S., Salvi, V., & Volpe, U. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031616 · Cited by 171 · cited 1×
“While a variety of peripheral biomarkers, such as C-reactive protein and inflammatory markers, are under investigation to assist in treatment selection, they are not yet validated or used in widespread clinical practice [19, 20].”
BackgroundTordera, R. M., Totterdell, S., Wojcik, S. M., Brose, N., Elizalde, N., Lasheras, B., & Del Rio, J. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.05259.x · Cited by 169
Smith-Apeldoorn, S. Y., Veraart, J. K., Spijker, J., Kamphuis, J., & Schoevers, R. A. (2022) · The Lancet Psychiatry · doi:10.1016/s2215-0366(22)00317-0 · Cited by 169 · cited 1×
“In TRD, the effectiveness of ketamine does not decline with repeated treatment, although effectiveness varies in clinical practice [72, 73], and there is insufficient evidence on its long-term efficacy and tolerability [66].”
BackgroundGlutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments
Kadriu, B., Musazzi, L., Henter, I. D., Graves, M., Popoli, M., & Zarate, C. A. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy094 · Cited by 165
Sanacora, G., & Schatzberg, A. F. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2014.261 · Cited by 160
The mechanisms of tolerance in antidepressant action
Fava, G. A., & Offidani, E. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.07.026 · Cited by 158 · cited 1×
“The central nervous system can adapt to sequential monoamine antidepressant exposure via acquired or oppositional tolerance, which may contribute to resistance [31, 32].”
BackgroundOrrego, F., & Villanueva, S. (1993) · Neuroscience · doi:10.1016/0306-4522(93)90355-j · Cited by 156
New targets for rapid antidepressant action
Machado-Vieira, R., Henter, I. D., & Zarate Jr., C. A. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.12.001 · Cited by 154
Impact of Major Depressive Disorder on Comorbidities: A Systematic Literature Review
Arnaud, A. M., Brister, T. S., Duckworth, K., Foxworth, P., Fulwider, T., Suthoff, E. D., Werneburg, B., Aleksanderek, I., & Reinhart, M. L. (2022) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.21r14328 · Cited by 149 · cited 1×
“MDD is accompanied by a range of other symptoms, is associated with comorbidities, and is a risk factor for both development and worsening of cardiovascular disease, metabolic disorders, diabetes, and substance use disorders [3, 6].”
BackgroundPillinger, T., Howes, O. D., Correll, C. U., Leucht, S., Huhn, M., Schneider-Thoma, J., Gaughran, F., Jauhar, S., McGuire, P. K., Taylor, D. M., et al. (2023) · The Lancet Psychiatry · doi:10.1016/s2215-0366(23)00262-6 · Cited by 147
Martinotti, G., Vita, A., Fagiolini, A., Maina, G., Bertolino, A., Dell'Osso, B., Siracusano, A., Clerici, M., Bellomo, A., Sani, G., et al. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.09.043 · Cited by 146 · cited 2×
“No unexpected safety signals were identified in these studies [133–135].”
BackgroundResultInfluentialSelf-citationDemoralization in suicide: A systematic review
Costanza, A., Chytas, V., Ambrosetti, J., Shah, S., Amerio, A., Aguglia, A., Serafini, G., Piguet, V., Luthy, C., Cedraschi, C., et al. (2022) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2022.110788 · Cited by 143
Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status
Henter, I. D., Park, L. T., & Zarate, C. A. (2021) · CNS Drugs · doi:10.1007/s40263-021-00816-x · Cited by 142 · cited 6×
“BDNF signaling, downstream of glutamate activation of AMPAR, is decreased in the brains of people with depression [14, 37].”
BackgroundMethodInfluentialIsHak, W. W., Mirocha, J., James, D., Tobia, G., Vilhauer, J., Fakhry, H., Pi, S., Hanson, E., Nashawati, R., Peselow, E. D., et al. (2015) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12301 · Cited by 140
Tabuteau, H., Jones, A., Anderson, A., Jacobson, M., & Iosifescu, D. V. (2022) · American Journal of Psychiatry · doi:10.1176/appi.ajp.21080800 · Cited by 140 · cited 6×
“…quinidine, was investigated in a 2016 phase 2 study for treatment of MDD (NCT02153502); however, the sponsor reported that it halted development of this agent in depression because results of the phase 2 trial did not provide sufficient evidence of efficacy to justify continued development [142].”
BackgroundMethodInfluentialIosifescu, D. V., Jones, A., O’Gorman, C., Streicher, C., Feliz, S., Fava, M., & Tabuteau, H. (2022) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.21m14345 · Cited by 135 · cited 5×
“Additionally, at week 6, AXS-05 treatment improved patient reported outcomes of function and quality of life compared with placebo (SDS nominal P < 0.05; Quality of Life Enjoyment and Satisfaction Questionnaire – Short Form nominal P < 0.05) [141].”
BackgroundInfluentialQuiroz, J. A., Tamburri, P., Deptula, D., Banken, L., Beyer, U., Rabbia, M., Parkar, N., Fontoura, P., & Santarelli, L. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2016.0838 · Cited by 133
Dwyer, J. M., & Duman, R. S. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.11.011 · Cited by 132
Jelen, L. A., & Stone, J. M. (2021) · International Review of Psychiatry · doi:10.1080/09540261.2020.1854194 · Cited by 124
Therapeutic potential of N-methyl-D-aspartate receptor modulators in psychiatry
Hanson, J. E., Yuan, H., Perszyk, R. E., Banke, T. G., Xing, H., Tsai, M.-C., Menniti, F. S., & Traynelis, S. F. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-023-01614-3 · Cited by 113
Saragoussi, D., Christensen, M. C., Hammer-Helmich, L., Rive, B., Touya, M., & Haro, J. M. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s159276 · Cited by 110
A Novel Binding Mode Reveals Two Distinct Classes of NMDA Receptor GluN2B-selective Antagonists
Stroebel, D., Buhl, D. L., Knafels, J. D., Chanda, P. K., Green, M., Sciabola, S., Mony, L., Paoletti, P., & Pandit, J. (2016) · Molecular Pharmacology · doi:10.1124/mol.115.103036 · Cited by 108
Deyama, S., Bang, E., Wohleb, E. S., Li, X.-Y., Kato, T., Gerhard, D. M., Dutheil, S., Dwyer, J. M., Taylor, S. R., Picciotto, M. R., et al. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.17121368 · Cited by 100
A Word to the Wise About Intranasal Esketamine
Schatzberg, A. F. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19040423 · Cited by 96 · cited 1×
“Additionally, the activity of esketamine at opioid receptors may worsen abuse potential and some urge for caution in prescribing esketamine until its long-term effects are known, including relapse and suicide risk upon discontinuation [132].”
BackgroundGlutamine deficiency in the prefrontal cortex increases depressive-like behaviours in male mice
Lee, Y., Son, H., Kim, G., Kim, S., Lee, D. H., Roh, G. S., Kang, S. S., Cho, G. J., Choi, W. S., & Kim, H. J. (2013) · Journal of Psychiatry & Neuroscience · doi:10.1503/jpn.120024 · Cited by 94
Pigott, H. E., Kim, T., Xu, C., Kirsch, I., & Amsterdam, J. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-063095 · Cited by 93 · cited 2×
“In patients who underwent multiple rounds of therapy, the probability of response or remission decreased with subsequent treatments, with only 21% response (22/106) and 10% remission (11/106) by the fourth therapy option [18].”
BackgroundWeisser, B., Predel, H., Gillessen, A., Hacke, C., Esche, J. V. D., Rippin, G., Noetel, A., & Randerath, O. (2020) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-020-00370-5 · Cited by 91
Fava, M., Stahl, S., Pani, L., De Martin, S., Pappagallo, M., Guidetti, C., Alimonti, A., Bettini, E., Mangano, R. M., Wessel, T., et al. (2022) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2021.21020197 · Cited by 83
Revisiting the sigma-1 receptor as a biological target to treat affective and cognitive disorders
Sałaciak, K., & Pytka, K. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.10.037 · Cited by 78
Rossom, R. C., Shortreed, S., Coleman, K. J., Beck, A., Waitzfelder, B. E., Stewart, C., Ahmedani, B. K., Zeber, J. E., & Simon, G. E. (2016) · Depression and Anxiety · doi:10.1002/da.22532 · Cited by 77
The influence of ketamine on drug discovery in depression
Kraus, C., Wasserman, D., Henter, I. D., Acevedo-Diaz, E., Kadriu, B., & Zarate, C. A. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.07.007 · Cited by 75 · cited 1×
“2) [69].”
Stahl, S. M. (2019) · CNS Spectrums · doi:10.1017/s1092852919001470 · Cited by 73
What Are the Implications of the STAR*D Trial for Primary Care?: A Review and Synthesis
Huynh, N. N., & McIntyre, R. S. (2008) · The Primary Care Companion to The Journal of Clinical Psychiatry · doi:10.4088/pcc.v10n0201 · Cited by 72
Self-citationOral ketamine for depression: An updated systematic review
Meshkat, S., Haikazian, S., Vincenzo, J. D. D., Fancy, F., Johnson, D. E., Chen-Li, D. C. J., McIntyre, R. S., Mansur, R. B., & Rosenblat, J. D. (2023) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2023.2169349 · Cited by 70
Self-citationElevated peripheral blood glutamate levels in major depressive disorder
Inoshita, M., Umehara, H., Watanabe, S.-Y., Nakataki, M., Kinoshita, M., Tomioka, Y., Tajima, A., Numata, S., & Ohmori, T. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s159855 · Cited by 67
Park, L. T., Kadriu, B., Gould, T. D., Zanos, P., Greenstein, D., Evans, J. W., Yuan, P., Farmer, C. A., Oppenheimer, M., George, J. M., et al. (2020) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa025 · Cited by 63
Murrough, J. W., Stade, E., Sayed, S., Ahle, G., Kiraly, D. D., Welch, A., Collins, K. A., Soleimani, L., Iosifescu, D. V., & Charney, D. S. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.04.072 · Cited by 62 · cited 1×
“In a small, open-label phase 2A study in 20 patients with TRD, oral dextromethorphan (45 mg)–quinidine (10 mg) improved depression symptoms from baseline, with 45% response and 35% remission rates, although the open-label design and lack of a control arm limit interpretation of the results [107].”
BackgroundAlmohammed, O. A., Alsalem, A., Almangour, A., Alotaibi, L. H., Yami, M. S. A., & Lai, L. (2022) · PLoS ONE · doi:10.1371/journal.pone.0265928 · Cited by 61
Hascup, K. N., Hascup, E. R., Humeidan, M., Glaser, P. E. A., Yoshitake, T., Mathé, A. A., Gerhardt, G. A., & Kehr, J. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.60 · Cited by 60
Sigma-1 Receptors in Depression: Mechanism and Therapeutic Development
Ren, P., Wang, J., Li, N., Li, G., Ma, H., Zhao, Y., & Li, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.925879 · Cited by 59
Takahashi, N., Yamada, A., Shiraishi, A., Shimizu, H., Goto, R., & Tominaga, Y. (2021) · BMC Psychiatry · doi:10.1186/s12888-021-03538-y · Cited by 57
Subcutaneous Ketamine in Depression: A Systematic Review
Cavenaghi, V. B., da Costa, L. P., Lacerda, A. L. T., Hirata, E. S., Miguel, E. C., & Fráguas, R. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.513068 · Cited by 54
Samalin, L., Rothärmel, M., Mekaoui, L., Gaudré-Wattinne, E., Codet, M.-A., Bouju, S., & Sauvaget, A. (2022) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2022.2030757 · Cited by 54
Wang, S.-M., Kim, N.-Y., Na, H.-R., Lim, H. K., Woo, Y. S., Pae, C.-U., & Bahk, W.-M. (2021) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2021.19.2.341 · Cited by 52
Majeed, A., Xiong, J., Teopiz, K. M., Ng, J., Ho, R., Rosenblat, J. D., Phan, L., Cao, B., & McIntyre, R. S. (2021) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2021.1898588 · Cited by 48
Self-citationBrendle, M., Ahuja, S., Valle, M. D., Moore, C., Thielking, P. D., Malone, D. C., & Robison, R. J. (2022) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2022-0149 · Cited by 47
Pothula, S., Liu, R.-J., Wu, M., Sliby, A., Picciotto, M. R., Banerjee, P., & Duman, R. S. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-00882-7 · Cited by 35
Chen, X., Hou, X., Bai, D., Lane, R., Zhang, C., Canuso, C., Wang, G., & Fu, D.-J. (2023) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s391096 · Cited by 35
Esmethadone-HCl (REL-1017): a promising rapid antidepressant
Fava, M., Stahl, S. M., Martin, S. D., Mattarei, A., Bettini, E., Comai, S., Alimonti, A., Bifari, F., Pani, L., Folli, F. B., et al. (2023) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-023-01571-4 · Cited by 32
Hsu, T., Chu, C., Ching, P., Chen, G., & Pan, C. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.03.047 · Cited by 30
Intrinsic Connectivity Networks of Glutamate-Mediated Antidepressant Response: A Neuroimaging Review
Demchenko, I., Tassone, V. K., Kennedy, S. H., Dunlop, K., & Bhat, V. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.864902 · Cited by 29 · cited 1×
“Clinically, a wide range of imaging studies, predominantly functional magnetic resonance imaging, have confirmed that ketamine treatment is associated with alterations within and between intrinsic connectivity networks implicated in depression, as reviewed in detail in Demchenko et al. [67].”
BackgroundDijkstra, F. M., O’Donnell, P., Klaassen, E. S., Buhl, D. L., Asgharnejad, M., Rosen, L. B., Zuiker, R. G. J. A., van Gerven, J., & Jacobs, G. E. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02148-w · Cited by 28
Baune, B. T., Florea, I., Ebert, B., Touya, M., Ettrup, A., Hadi, M., & Ren, H. (2021) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s325954 · Cited by 26
Zhang, X.-Y., Ji, F., Wang, N., Chen, L., Tian, T., & Lü, W. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.570630 · Cited by 25
Ahuja, S., Brendle, M., Smart, L., Moore, C., Thielking, P., & Robison, R. (2022) · BMC Psychiatry · doi:10.1186/s12888-022-04268-5 · Cited by 24 · cited 1×
“While there have been fewer studies investigating intramuscular, oral, or subcutaneous ketamine formulations, initial evidence is suggestive of efficacy and safety when used under close medical supervision [74–77].”
BackgroundWatanabe, M., Marcy, B., Hiroki, A., Watase, H., Kinoshita, K., Iijima, M., Marumo, T., Zarate, C. A., & Chaki, S. (2022) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyab062 · Cited by 22
Touya, M., Lawrence, D. F., Kangethe, A., Chrones, L., Evangelatos, T., & Polson, M. (2022) · BMC Psychiatry · doi:10.1186/s12888-022-03793-7 · Cited by 21 · cited 1×
“High relapse rates correlate with increased public health burden, hospitalization, and costs [24].”
BackgroundTranscranial magnetic stimulation as a translational biomarker for AMPA receptor modulation
O’Donnell, P., Dijkstra, F. M., Damar, U., Lei, Q., de Goede, A. A., Xu, L., Pascual-Leone, A., Buhl, D. L., Zuiker, R. G. J. A., Ruijs, T. Q., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01451-2 · Cited by 21
Longer-term open-label study of adjunctive riluzole in treatment-resistant depression
Sakurai, H., Dording, C., Yeung, A., Foster, S., Jain, F., Chang, T., Trinh, N.-H., Bernard, R., Boyden, S., Iqbal, S. Z., et al. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.06.065 · Cited by 20 · cited 2×
“Riluzole can inhibit the release of presynaptic glutamate and interact with ionotropic receptors [84].”
BackgroundResultNemeroff, C. B. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18010014 · Cited by 19
Yao, R., Wang, H., Yuan, M., Wang, G., & Wu, C. (2020) · Psychiatry Research · doi:10.1016/j.psychres.2020.112750 · Cited by 16
Ghaemi, N., Sverdlov, A., Shelton, R., & Litman, R. (2021) · European Psychiatry · doi:10.1192/j.eurpsy.2021.897 · Cited by 15
Gomez‐Mancilla, B., Levy, J. A., Ganesan, S., Faller, T., Issachar, G., Peremen, Z., Laufer, O., Shani‐Hershkovich, R., Biliouris, K., Walker, E., et al. (2023) · Clinical and Translational Science · doi:10.1111/cts.13623 · Cited by 12
Andrews, P. W., & Amsterdam, J. D. (2020) · Psychiatria Polska · doi:10.12740/pp/120084 · Cited by 11
Generic initiation and antidepressant therapy adherence under Medicare Part D.
Bao, Y., Ryan, A. M., Shao, H., Pincus, H. A., & Donohue, J. M. (2013) · PubMed · Cited by 11
Lee, W., Sheehan, C., Chye, R., Chang, S., Bayes, A. J., Loo, C. K. A., Draper, B., Agar, M. R., & Currow, D. C. (2023) · PLoS ONE · doi:10.1371/journal.pone.0290876 · Cited by 11
Jones, A., Streicher, C., Alter, S. P., Thomas, Z., & Tabuteau, H. (2023) · CNS Spectrums · doi:10.1017/s1092852923001840 · Cited by 3
Research works printed but not linked: 2
- Réus GZ, Quevedo J, Lúcia S, Rodrigues A. Mtor signaling in the neuropathophysiology of depression: current evidence. J Recept Ligand Channel Res. 2015;65:78.
- Paterson B, Fraser H, Wang C, et al. A randomized, double-blind, placebo-controlled, sequential parallel study of cerc-301 in the adjunctive treatment of subjects with severe depression and recent active suicidal ideation despite antidepressant treatment. National Network of Depression Centers Annual Conference; Ann Arbor, MI. 2015.
Cited by
Antos, Z., Żukow, X., Bursztynowicz, L., & Jakubów, P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413658 · Cited by 21
d’Andrea, G., Cavallotto, C., Pettorruso, M., Lorenzo, G. D., Carullo, R., Berardis, D. D., Rosso, G., Barlati, S., Martiadis, V., Tamagnini, G., et al. (2025) · Psychiatry Research · doi:10.1016/j.psychres.2025.116655 · Cited by 26
Self-citationCheng, M. C. H., Dri, C. E., Ballum, H., Valentino, K., Cheung, W., Teopiz, K. M., Wong, S., & McIntyre, R. S. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.04.119 · Cited by 18
Self-citationPharmacological Monotherapy for Depressive Disorders: Current and Future—A Narrative Review
Gao, K., Oruc, E. B., & Koparal, B. (2025) · Medicina · doi:10.3390/medicina61040558 · Cited by 14
Nagpurkar, K., Ghive, P., Kale, M. B., Nistane, N. T., Taksande, B. G., Umekar, M. J., & Trivedi, R. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.05.022 · Cited by 12
Metadata
- Authors
- McIntyre, R. S., & Jain, R.
- Affiliations
- University of Toronto (CA)
- Texas Tech University (US)
- Corresponding author
- Jain, Rakesh
- Venue
- CNS Drugs
- Published
- 2024-08-16
- Volume
- 38
- Issue
- 11
- Pages
- 869-890
- ISSN
- 1172-7047 (ISSN-L)
- 1179-1934
- PMC
- PMC11486832
- OpenAlex
- W4401654837
- Cited by
- 69
- References
- 133
- Citations by year
- 2026: 33 · 2025: 34 · 2024: 2
- FWCI
- 4.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor)
- Locations
- CNS Drugs (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Axsome Therapeutics., Inc.
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- major depressive disorder, glutamate signaling, NMDA receptor, ketamine, esketamine, treatment-resistant depression, synaptogenesis, neuroplasticity, antidepressant drug development, anhedonia, suicidal ideation, intranasal administration, drug safety and tolerability
- MeSH terms
- Animals, Antidepressive Agents, Major Depressive Disorder, Humans, Ketamine, Excitatory Amino Acid Agents, Glutamic Acid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.